SCHEMBL4407643

SCHEMBL4407643

CCOc1cc(O)c(F)c(C(=O)O)c1Cl

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 4/20 0.40
HSD17B10 Q99714 1/20 0.40
MAPK1 P28482 2/20 0.39
KDM4E B2RXH2 1/20 0.39
NPC1 O15118 1/20 0.39
MITF O75030 1/20 0.39
THRB P10828 1/20 0.39
RAB9A P51151 1/20 0.39
HTT P42858 2/20 0.38
POLB P06746 2/20 0.38
ALOX15 P16050 2/20 0.38
LMNA P02545 3/20 0.37
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
GAA P10253 3/20 0.36
MCL1 Q07820 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
CYP3A4 P08684 1/20 0.36
ALDH1A1 P00352 2/20 0.36
RORC P51449 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4405901 0.88 MAPK1 (0.37) TSHRHSD17B10MAPK1KDM4ENPC1
SCHEMBL4408951 0.84 TSHR (0.47) TSHRHSD17B10MAPK1KDM4ENPC1
SCHEMBL4411775 0.83 MEN1 (0.43) HSD17B10MAPK1KDM4ERAB9AHTT
SCHEMBL4412805 0.81 TSHR (0.47) TSHRHSD17B10MAPK1KDM4ENPC1
SCHEMBL4395573 0.79 THRB (0.40) TSHRHSD17B10MAPK1KDM4ENPC1
SCHEMBL4398918 0.76 MAPT (0.36) TSHRHSD17B10MAPK1KDM4ENPC1
SCHEMBL4410404 0.75 TSHR (0.47) TSHRHSD17B10MAPK1KDM4ENPC1
SCHEMBL4414696 0.75 ALDH1A1 (0.34) TSHRMAPK1KDM4ENPC1MITF
SCHEMBL4404617 0.73 PTGS2 (0.42) HSD17B10MAPK1KDM4ERAB9AHTT
SCHEMBL4399086 0.73 KDM4E (0.40) TSHRHSD17B10MAPK1KDM4EHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1549651-B1 PYRIMIDOPYRIMIDONES AS KINASE INHIBITORS WARNER LAMBERT CO (US) 2009-12-23 EP disclosed
US-7196090-B2 Kinase inhibitors WARNER-LAMBERT COMPANY (US) 2007-03-27 US disclosed
EP-1549651-A1 KINASE INHIBITORS Warner-Lambert Company LLC (US) 2005-07-06 EP disclosed
WO-2004011465-A1 KINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-02-05 WO disclosed
US-20040019210-A1 Kinase inhibitors CHIVIKAS CONNOLLY CLEO J (US) 2004-01-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040019210-A1 Kinase inhibitors CDK2, CDK1, CDK4 TSHR 3028/4885HSD17B10 2499/4885MAPK1 91/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.